Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Salivary Gland Neoplasms × pazopanib × Head & Neck × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thyroid Neoplasms 5 Breast Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Head and Neck Neoplasms 2 Thyroid Carcinoma, Anaplastic 1 Thyroid Cancer, Papillary 1 Salivary Gland Neoplasms 1 Recurrent Lymphoepithelioma of the Nasopharynx 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Kidney Neoplasms 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Medullary 1 Adenocarcinoma, Follicular 1

Interventions

Docetaxel 16 Cisplatin 15 Carboplatin 12 Radiotherapy 9 Magnetic Resonance Spectroscopy 9 Cetuximab 9 Biopsy 9 pembrolizumab 8 Paclitaxel 8 Immunohistochemistry 8 Erlotinib Hydrochloride 8 Trastuzumab 7 Radiotherapy, Intensity-Modulated 7 Chemotherapy, Adjuvant 7 Specimen Handling 6 Gemcitabine 6 Radiotherapy, Conformal 5 Vorinostat 4 Taxes 4 Radiosurgery 4 Gene Expression Profiling 4 Fluorodeoxyglucose F18 4 Capecitabine 4 Bevacizumab 4 trastuzumab deruxtecan 3 darolutamide 3 Surgical Procedures, Operative 3 Sorafenib 3 Radiation 3 Polymerase Chain Reaction 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02393820 2019-10-29

PACSA-ORL02

UNICANCER

Phase 2 Completed

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡